오리엔트바이오

002630KOSPI

55.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 51.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Orient Bio operates in the biotechnology infrastructure sector, specializing in SPF egg production, CRO clinical trial services, and the development of bio-experimental equipment and biological materials, while adhering to international standards such as ICH, GLP, and GMP. The biotechnology industry, characterized by high added value and growth potential, is a key focus area for the company, contributing to healthcare, research, and pharmaceutical sectors.

Number of Employees

123people

Average Salary

32.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.57Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-16.82Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

12.14Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼260.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.2% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (66%)

Current 1,386Won52-week high 1,85352-week low 467

1-month return6.0Point

1m +51.81% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0